Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Bevacizumab 55Cetuximab 52Fluorouracil 45Oxaliplatin 39Leucovorin 38pembrolizumab 34Specimen Handling 29Irinotecan 24Magnetic Resonance Spectroscopy 18Biopsy 18Nivolumab 17Capecitabine 14trifluridine tipiracil drug combination 13HMPL-013 13Folfox protocol 13Panitumumab 12Gemcitabine 12Cisplatin 12Carboplatin 11encorafenib 9balstilimab 9Standard of Care 9Pemetrexed 9IFL protocol 9Trifluridine 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × berzosertib × 90 days × Clear all
NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡